The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 08, 2015
Filed:
Jun. 11, 2009
Xin W. Wang, Rockville, MD (US);
Junfang Ji, Bethesda, MD (US);
Carlo M. Croce, Columbus, OH (US);
Hui-chuan Sun, Shanghai, CN;
Zhao-you Tang, Shanghai, CN;
Xin W. Wang, Rockville, MD (US);
Junfang Ji, Bethesda, MD (US);
Carlo M. Croce, Columbus, OH (US);
Hui-chuan Sun, Shanghai, CN;
Zhao-you Tang, Shanghai, CN;
The Ohio State University, Columbus, OH (US);
Fudan University, Shanghai, CN;
The United States of America as Represented by the Secretary of the Dept. of Health and Human Services, Washington, DC (US);
Abstract
It is disclosed herein that expression of microRNA-26 is decreased in hepatocellular (HCC) tumor tissue relative to non-cancerous tissue, and that a low level of microRNA-26 is associated with a poor clinical outcome. It is also disclosed herein that a low expression level of microRNA-26 is correlated with a favorable response to interferon (IFN)-α therapy in HCC patients. Thus, provided herein is a method of predicting the clinical outcome of a patient diagnosed with HCC comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. Also provided is a method of selecting a patient diagnosed with HCC as a candidate for IFN-α therapy, comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. A method of identifying therapeutic agents for the treatment of HCC, comprising screening candidate agents in vitro to select an agent that increases expression of microRNA-26 in HCC cells are also provided. Further provided are methods of treating a patient diagnosed with HCC and expressing a low level of miR-26, wherein treatment comprises IFN-α therapy.